Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 3

4(80.0%)

Phase 4

1(20.0%)

5Total

Phase 3(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07486687Phase 3Not Yet Recruiting

Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

Role: collaborator

NCT07260435Phase 3Recruiting

Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer

Role: collaborator

NCT06714838Phase 3Recruiting

Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Role: collaborator

NCT05834855Phase 3Recruiting

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

Role: collaborator

NCT04225312Phase 4Unknown

Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

Role: collaborator

All 5 trials loaded